Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

By E. Missiaglia, B. Jacobs, Giovanni D'Ario, A. D. Narzo, Charlotte Soneson, E. Budinská, V. Popovici, L. Vecchione, S. Gerster, P. Yan and 5 more. Annals of Oncology, 2014

603 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2cca9048f27d72c1e1869463fb858dbfcb1b67ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Nikolaus Schultz
2. Fortunato Ciardiello

Citations in the corpus

• Clinical sequencing defines the genomic landscape of metastatic colorectal cancer (2018, background): “…whether ligand expression may be activating mitogenic signaling in these tumors, we analyzed levels of ligand expression in TCGA non-hypermutated CRCs. Previous studies indicated increased amphiregulin and epiregulin expres- sion in the left colon (Lee et al., 2016; Missiaglia et al., 2014).”
• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, background): “Active signalingvia theEGFRpathway ismore frequent in patients with left-sided tumors, ostensibly rendering them more responsive to EGFR inhibitor–based therapy.(5,21) Patients with right-sided tumors have poor prognosis, which arises independent of BRAF status and does not appear to be successfully”